Filing Details
- Accession Number:
- 0001567619-19-010640
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-13 17:52:44
- Reporting Period:
- 2019-05-09
- Accepted Time:
- 2019-05-13 17:52:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
827871 | Eagle Pharmaceuticals Inc. | EGRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1495110 | L Douglas Braunstein | C/O Hudson Executive Capital Lp 570 Lexington Avenue, 35Th Floor New York NY 10022 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2019-05-09 | 59,223 | $57.95 | 911,777 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2019-05-10 | 100,000 | $56.14 | 811,777 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $57.94 to $58.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- These securities are held for the account of certain private investment funds (the "HEC Funds") for which Hudson Executive Capital LP, a Delaware limited partnership ("HEC"), acts as investment adviser. The Reporting Person controls the general partner of HEC and indirectly controls the general partner of the HEC Funds. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.